transcription factor A, mitochondrial pseudogene 2Genealiases: MTTF1 · TCF6L3
Q-omics provides the consensus-scored TFAMP2 profile across patient tissues and cancer cell-line models. TFAMP2 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TFAMP2 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, TFAMP2 RNA expression shows 6,713 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight MESO, BRCA, and COAD as cancer lineages where TFAMP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TFAMP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TFAMP2 survival associations across molecular data types. TFAMP2 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TFAMP2 RNA expression–survival associations across cancer types. High TFAMP2 expression shows unfavorable associations in MESO, CHOL, THCA, KIRC and SKCM, but favorable associations in ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TFAMP2 RNA expression.
This table summarizes TFAMP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TFAMP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TFAMP2 shows higher tumor expression in BRCA. The BRCA box plot shows higher TFAMP2 RNA expression in tumor versus normal tissue (log2 FC = +0.004, t-test p = .044).
This table shows molecular features associated with TFAMP2 in patient tissues and cancer cell lines. In patient samples, TFAMP2 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
